# US 2006/0153833 A1 · Anti hepatitis C virus antibody and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2006/0153833 A1
- Document ID: US20060153833A1
- Status: Published application
- Kind: A1
- Application number: 10/972,296
- Filed: 2004-10-25
- Published: 2006-07-13
- Earliest claimed: 1998-07-21
- Assignees: Genmab A/S
- Inventors: Christian Reiter; Francois Habersetzer; Anne Fournillier; Christian Trepo; Claude Desgranges; Genevieve Inchauspe
- Web page: https://patentgrep.com/patent/US20060153833A1

## CPC

- G01N 33/5767: {non-A, non-B hepatitis}
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- C07K 16/118: Hepatitis C virus; GB virus C [GBV-C]
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Described are novel antibodies specifically recognizing conformation dependent epitopes of HCV glycoprotein E2 and that are capable aof neutralizing the binding of E2 protein onto susceptible cells. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are to vectors comprising said polynucleotides as well as host cells transformed therewith and their use in the production of said antibodies. In addition, pharmaceutical and diagnostic compositions are provided comprising any of the aforedescribed antibodies, antigens, epitopes, polynucleotides, vectors or cells. Further described is the use of the aforementioned antibodies, antigens, polynucleotides and vectors in adoptive immunotherapy, preferably for the treatment or prevention of HCV infection during liver transplantation.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody, wherein said antibody comprises at least a VH complementarity determining region (CDR) 3 (CDR3) having amino acids 98-106 of SEQ ID NO: 4, which antibody specifically recognizes a conformation-dependent epitope of Hepatitis C Virus (HCV) glycoprotein E2 and precipitates covalently or non-covalently associated E2/E1 complexes.

### Claim 23

A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an antibody, wherein said antibody specifically recognizes the same conformation-dependent epitope of Hepatitis C Virus (HCV) E2 present on HCV genotypes 1a, 1b, 2a, 3a and 4 as that bound by an antibody comprising at least a VH complementarity determining region (CDR) 3 (CDR3) having amino acids 98-106 of SEQ ID NO: 4, and precipitates covalently or non-covalently associated E2/E1 complexes.

### Claim 24 (depends on 22, 23)

The pharmaceutical composition of claim 22 or 23, wherein said antibody is a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody, a synthetic antibody, or an antigen-binding antibody fragment.

### Claim 25 (depends on 24)

The pharmaceutical composition of claim 24, wherein said antibody is a monoclonal antibody.

### Claim 26 (depends on 22)

The pharmaceutical composition of claim 22, wherein said antibody further comprises one or more of a VH CDR1 having amino acids 31-35 of SEQ ID NO: 4, a VH CDR2 having amino acids 50-65 of SEQ ID NO: 4, a VL CDR1 having amino acids 23-33 of SEQ ID NO: 2, a VL CDR2 having amino acids 49-55 of SEQ ID NO: 2 or a VL CDR3 having amino acids 88-98 of SEQ ID NO: 2.

### Claim 27 (depends on 22, 23)

The pharmaceutical composition of claim 22 or 23, wherein said antibody comprises the VH amino acid sequence SEQ ID NO: 4.

### Claim 28 (depends on 22, 23)

The pharmaceutical composition of claim 22 or 23, wherein said antibody comprises the VH amino acid sequence SEQ ID NO: 4 and the VL amino acid sequence SEQ ID NO: 2.

### Claim 29 (depends on 25)

The pharmaceutical composition of claim 25, wherein said antibody is a human monoclonal antibody.

### Claim 30 (depends on 22, 23)

The pharmaceutical composition of claim 22 or 23, wherein said pharmaceutical composition is for administering to liver transplantation subjects.

### Claim 31 (depends on 30)

The pharmaceutical composition of claim 30, wherein said administering is prior, during and/or after said transplantation.

### Claim 32

A method of treatment comprising administering a therapeutically effective amount of a pharmaceutical composition to a subject in need thereof, wherein said pharmaceutical composition comprises a pharmaceutically acceptable carrier and an antibody, which antibody comprises at least a VH complementarity determining region (CDR) 3 (CDR3) having amino acids 98-106 of SEQ ID NO: 4, and which antibody specifically recognizes a conformation-dependent epitope of Hepatitis C Virus (HCV) glycoprotein E2 and precipitates covalently or non-covalently associated E2/E1 complexes.

### Claim 33

A method of treatment comprising administering a therapeutically effective amount of a pharmaceutical composition to a subject in need thereof, said composition comprising a pharmaceutically acceptable carrier and an antibody, wherein said antibody specifically recognizes the same conformation-dependent epitope of HCV E2 present on HCV genotypes 1a, 1b, 2a, 3a and 4 as that bound by an antibody comprising at least a VH complementarity determining region (CDR) 3 (CDR3) having amino acids 98-106 of SEQ ID NO: 4, and precipitates covalently or non-covalently associated E2/E1 complexes.

### Claim 34 (depends on 32, 33)

The method of claim 32 or 33, wherein said antibody is a monoclonal antibody, a polyclonal antibody, a chimeric antibody, a humanized antibody, a synthetic antibody, or an antigen-binding antibody fragment.

### Claim 35 (depends on 32)

The method of claim 32, wherein said antibody further comprises one or more of a VH CDR1 having amino acids 31-35 of SEQ ID NO: 4, a VH CDR2 having amino acids 50-65 of SEQ ID NO: 4, and a VL CDR1 having amino acids 23-33 of SEQ ID NO: 2, a VL CDR2 having amino acids 49-55 of SEQ ID NO: 2 or a VL CDR3 having amino acids 88-98 of SEQ ID NO: 2.

### Claim 36 (depends on 34)

The method of claim 34, wherein said antibody is a monoclonal antibody.

### Claim 37 (depends on 32, 33)

The method of claim 32 or 33, wherein said antibody comprises the VH amino acid sequence SEQ ID NO: 4.

### Claim 38 (depends on 32, 33)

The method of claim 32 or 33, wherein said antibody comprises the VH amino acid sequence SEQ ID NO: 4 and the VL amino acid sequence SEQ ID NO: 2.

### Claim 39 (depends on 36)

The method of claim 36, wherein said antibody is a human monoclonal antibody.

### Claim 40 (depends on 32, 33)

The method of claim 32 or 33, wherein said treatment is the treating or preventing of infection of Hepatitis C Virus, treating or preventing of re-infection of Hepatitis C Virus, or alleviating chronic Hepatitis C in said subject.

### Claim 41 (depends on 40)

The method of claim 40, wherein said subject is a human or an animal.

### Claim 42 (depends on 32, 33)

The method of claim 32 or 33, wherein said subject is having a liver transplant.

### Claim 43 (depends on 42)

The method of claim 42, wherein said composition is administered prior, during and/or after said transplantation.
